LIMN — Liminatus Pharma, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1971387 ·
Last close
$4.20
Market Cap
$5.63M
52W High
$141.50
52W Low
$3.29
ADV30
51,167
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,378,908 | -1,407,259 | 3,403,702 | 3,017,096 | 3,103,090 |
| Mar 2026 | 0 | — | -1,100,898 | -1,123,714 | 2,790,249 | 1,907,674 | 2,922,845 |
| Dec 2025 | 0 | — | -884,211 | -8,168,927 | 512,795 | 337,655 | 10,327,485 |
| Sep 2025 | 0 | — | -701,170 | -1,823,351 | 1,342,409 | 724,502 | 2,988,172 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,819,214
Investing CF
$-213,108
Financing CF
$13,905,070
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.11
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-39,995,447
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-11,271,265
Pretax Income TTM
$-11,443,518
Interest Exp TTM
$172,253
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -2,967,812 | -10,206,517 | 512,795 | 10,327,485 | -9,814,690 | -9,963,318 |
| Dec 2024 | 0 | -3,329,953 | -3,546,309 | 5,408,859 | 24,748,922 | -19,340,063 | -1,451,066 |
| Dec 2023 | 0 | -4,819,000 | -4,984,000 | 2,242,000 | 18,036,000 | 0 | -3,345,000 |
| Dec 2022 | 0 | -2,709,000 | -2,928,000 | 6,843,000 | 17,653,000 | 0 | -869,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PMCB | PharmaCyte Biotech, Inc. | $4.73M | $0.44 | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $6.79M | $1.03 | — |
| AIM | AIM ImmunoTech Inc. | $7.11M | $0.19 | — |
| CUBT | Curative Biotechnology Inc | $8.89M | $1.00 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $10.25M | $0.33 | — |
News headlines (Yahoo Finance, 1h cache)
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
2026-08-24 12:00 · Yahoo
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
2026-08-18 20:01 · Yahoo
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
2026-06-03 12:30 · Yahoo
Liminatus Pharma Announces Nasdaq Delisting Notification
2026-05-22 00:28 · Yahoo
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
2026-08-13 11:15 · Yahoo
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
2026-06-30 20:30 · Yahoo
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
2026-03-17 12:08 · Yahoo
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
2026-02-17 13:44 · Yahoo
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
2025-10-30 14:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.